{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "PAR", "shortName": "NEOVACS", "longName": "Neovacs S.A.", "messageBoardId": "finmb_6025615", "exchangeTimezoneName": "Europe/Paris", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "fr_market", "esgPopulated": false, "fullExchangeName": "Paris", "financialCurrency": "EUR", "regularMarketOpen": 0.0002, "averageDailyVolume3Month": 59044764, "averageDailyVolume10Day": 62738663, "fiftyTwoWeekLowChange": 0.0001, "fiftyTwoWeekLowChangePercent": 1.0, "fiftyTwoWeekRange": "1.0E-4 - 0.388", "fiftyTwoWeekHighChange": -0.3878, "fiftyTwoWeekHighChangePercent": -0.99948454, "fiftyTwoWeekLow": 0.0001, "fiftyTwoWeekHigh": 0.388, "trailingAnnualDividendRate": 0.0, "trailingPE": 0.000108108106, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 1.85, "epsForward": 0.1, "sharesOutstanding": 2484910080, "bookValue": 3.303, "fiftyDayAverage": 0.000466, "fiftyDayAverageChange": -0.000266, "fiftyDayAverageChangePercent": -0.57081544, "twoHundredDayAverage": 0.0308305, "twoHundredDayAverageChange": -0.030630501, "twoHundredDayAverageChangePercent": -0.9935129, "marketCap": 745472, "forwardPE": 0.0019999999, "priceToBook": 6.0551014e-05, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.0002, "marketState": "POSTPOST", "firstTradeDateMilliseconds": 1271833200000, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683905910, "regularMarketDayHigh": 0.0002, "regularMarketDayRange": "1.0E-4 - 2.0E-4", "regularMarketDayLow": 0.0001, "regularMarketVolume": 265259618, "regularMarketPreviousClose": 0.0002, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "symbol": "ALNEV.PA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "3-5, Impasse Reille", "city": "Paris", "zip": "75014", "country": "France", "website": "https://www.neovacs.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Hugo  Brugiere M.Sc.", "title": "Chairman, GM & CEO", "fiscalYear": 2020, "totalPay": {"raw": 85000, "fmt": "85k", "longFmt": "85,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Daniel  Zagury", "title": "Founder, Chairman of Scientific Research Committee & Director", "fiscalYear": 2020, "totalPay": {"raw": 6000, "fmt": "6k", "longFmt": "6,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Vincent  Serra", "age": 52, "title": "Scientific & Operational Director", "yearBorn": 1970, "fiscalYear": 2020, "totalPay": {"raw": 188798, "fmt": "188.8k", "longFmt": "188,798"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alexandre  Courtoux", "title": "Admin. & Financial Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Charlene  Masson", "title": "Corp. Communication & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Valerie  Salentey Ph.D.", "title": "Head of Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1609372800, "maxAge": 86400}}], "error": null}}